Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 16;190(3):431-432.
doi: 10.1093/bjd/ljad387.

Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative

Philippe Lefrançois  1 , Zein Doueidari  1 , Omer Kleiner, Rachael Manion, Jan Dutz, Anie Philip, An-Wen Chan; Skin Investigation Network of Canada Priority Setting Collaborative
Collaborators, Affiliations

Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative

Philippe Lefrançois et al. Br J Dermatol. .

Abstract

The Skin Investigation Network of Canada (SkIN Canada) completed a national priority-setting initiative to identify the top 10 knowledge uncertainties for SCC based on the James Lind Alliance principles. Overall, 64 patients, clinicians and researchers provided input in two survey rounds and one workshop. The top 10 list of research priorities will help the skin research community, funders and policymakers to address key knowledge uncertainties for the benefit of patients with SCC.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest P.L. has received grants from the Lady Davis Institute for Medical Research, from the Jewish General Hospital Foundation and from the Jewish General Hospital Department of Medicine for this work. R.M. is the executive director of the Canadian Skin Patient Alliance, and receives funding from governments, individuals and corporations, including pharmaceutical companies. A full list of sponsors can be viewed here: https://www.canadianskin.ca/about-us/sponsors. A.P. is an inventor on two patents covering the use of peptidic transforming growth factor-β antagonists as antifibrotic agents.

References

    1. Venables ZC, Nijsten T, Wong KF et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013–15: a cohort study. Br J Dermatol 2019; 181:474–82. - PMC - PubMed
    1. Tang E, Fung K, Chan A-W. Incidence and mortality rates of keratinocyte carcinoma from 1998–2017: a population-based study of sex differences in Ontario, Canada. CMAJ 2021; 193:E1516–24. - PMC - PubMed
    1. Muzic JG, Schmitt AR, Wright AC et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma. Mayo Clin Proc 2017; 92:890–8. - PMC - PubMed
    1. Migden MR, Rischin D, Schmults CD et al. PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379:341–51. - PubMed
    1. Chan A-W, Fung K, Austin PC et al. Improved keratinocyte carcinoma outcomes with annual dermatology assessment after solid organ transplantation: population-based cohort study. Am J Transplant 2019; 19:522–31. - PubMed

MeSH terms

Grants and funding